Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 134

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 134
---
 include:

    ●
    employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel-related expenses for our research and development personnel;

    ●
    expenses incurred under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) as well as consultants that support the implementation of our clinical and non-clinical studies;

16

    ●
    manufacturing and packaging costs in connection with conducting clinical trials;

    ●
    formulation, research and development expenses related to our TAEUS technology; and

    ●
    costs for sponsored research.

We plan to incur research and development expenses
for the foreseeable future as we expect to continue the development of TAEUS and pursue FDA approval of the NAFLD TAEUS system. At this
time, due to the inherently unpredictable nature of clinical development and regulatory approvals, we are unable to estimate with certainty
the costs we will incur and the timelines we will require in our continued development efforts.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily
of headcount and consulting costs, and marketing and tradeshow expenses. Currently, our marketing efforts are through our website and
attendance of key industry meetings and conferences. During the second quarter of 2024, we restructured our sales operations to better
align with the Company’s near-term sales prospects. We plan to begin staffing our sales efforts once we have obtained FDA approval
for the sale of the NAFLD TAEUS device.

General and Administrative Expenses

General and administrative expenses consist primarily
of salaries and related expenses for our management and personnel, and professional fees, such as for accounting, consulting and legal
services. We anticipate continued costs associated with being a public company, including expenses related to services associated with
maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting
costs and investor relations costs.

Critical Accounting Policies and Estimates    

Use of Estimates

The preparation of the financial statements in
conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements
and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Management makes estimates that affect certain
accounts including inventory reserve, deferred income tax assets, accrued expenses, fair value of equity instruments and reserves